In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine

Fundamental and Clinical Pharmacology

Volumn 12, Issue 2, 1998, Pages 194-199

  Iribarne, C ^a   Picart, D ^a   Dreano Y ^a   Berthou, F ^a  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

Author keywords

Buprenorphine; Fluoxetine; Fluvoxamine; Methadone

Indexed keywords

BUPRENORPHINE; FLUOXETINE; FLUVOXAMINE; METHADONE; NORFLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DEALKYLATION; DRUG DETERMINATION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER METABOLISM; LIVER MICROSOME; PRIORITY JOURNAL;

EID: 0031969424     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1998.tb00941.x     Document Type: Article

References (37)

1. Baciewicz AM, Self TH. Rifampin drug interactions. Arch Intern Med 1984 ; 144 : 1667-71
2. Batki SL, Manfredi LB, Jacob P, Jones RT. Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/ benzoylecgonine concentrations. J Clin Psychopharmacol 1993 ; 13 : 243-50
3. Berthou F, Dréano Y, Belloc C, Kangas L, Gautier JC, Beaune P. Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol 1994 ; 47 : 1883-95
4. Bertschy G, Baumann P, Eap CB, Baettig D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 1994 ; 16 : 42-5
5. Bertschy G, Eap CB, Powell K, Baumann P. Fluoxetine addition to methadone in addicts: Pharmacokinetic aspects. Ther Drug Monit 1996; 18 : 570-2
6. Best SE, Oliveto AH, Kosten TR. Opioid addiction. Recent advances in detoxification and maintenance therapy. CNS Drugs 1996; 6 : 301-14
7. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988 ; 43 : 72-8
8. Brosen K, Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of Ph50 IID6. The source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 1991 ; 32 : 136-7
9. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993 ; 45 : 1211-14
10. Chang THK, Gonzales FJ, Waxman DJ. Evaluation of triacetyloleandomycin, α-naphtoflavone and diethyldithiocarbamate as selective chemical probes of human cytochromes P450. Arch Biochem Biophys 1994 ; 311 : 437-42
11. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin reuptake inhibitors on cytochrome P450 2D6 (CYP 2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992 ; 34 : 262-5
12. Dole VP, Nyswander M. A medical treatment for diacetyl morphine (heroine) addiction. J Am Med Assoc 1965 ; 193 : 646-50
13. Eap CB, Bertschy G, Powell K, Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharma 1997 ; 17 : 113-17
14. Greenblatt DJ, Von Moltke LL, Schmider J, Harmatz JS, Shader RI. Inhibition of human cytochrome P450 3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J Clin Pharmacol 1996 ; 36 : 792-8
15. Guengerich FP. Human cytochrome P450 in Cytochrome P450. In: O de Montellano, ed. Structure, mechanism and biochemistry. New York: Plenum Press; 1995. p 473-535
16. Guengerich FP. In-vitro techniques for studying drug metabolism. J Pharmacokin Biopharm 1996 ; 25 : 521-33
17. Iribarne C, Berthou F, Baird S, Dréano Y, Picart D, Bail JP et al. Involvement of cytochrome P3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996 ; 9 : 365-73
18. Iribarne C, Picart D, Dréano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in the N-dealkylation of buprenorphine in human liver microsomes. Life Science 1997 ; 60 : 1953-64
19. Iribarne C, Dréano Y, Bardou LG, Ménez JF, Berthou F. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 1997 ; 117 : 13-23
20. Jacolot F, Simon I, Dréano Y, Beaune P, Riché C, Berthou F. Identification of the cytochrome P450 IIIA family as the enzyme involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 1991 ; 41 : 1911-19
21. Kosten TR, Rounsaville BJ, Kleber HD. A 2.5 years follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. Arch Gen Psychiatry 1986 ; 43 : 733-8
22. Kreek MJ. Biological correlates of methadone maintenance pharmacotherapy. Ann Med Interne 1994 ; 145 : 9-14
23. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Maurel P et al. The major pathway of imipramine metabolism is catalyzed by cytochrome P450 1A27 and 3A4 in human liver microsomes. Mol Pharmacol 1993 ; 43 : 827-32
24. Lucas J. The human pharmacology of fluoxetine. Int J Obes 1992 ; 16 : S49-54
25. Maiermani I, Castogiovanni P, Daini L, Zolest O. Use of fluoxetine in heroin addictions. Br J Psychiatry 1992 ; 160 : 570-1
26. Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, Maurel P. Effect of imidazole derivatives on cytochrome P450 from human hepatocytes in primary cultures. FASEB J 1992 ; 6 : 752-8
27. Mello NK, Mendelson JH. Buprenorphine suppresses heroin use by heroin addicts. Science 1980 ; 207 : 657-9
28. Okey AB. Enzyme induction in the cytochrome P450 system. Pharmac Ther 1990 ; 45 : 241-98
29. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993 ; 53 : 401-9
30. Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Pharmacokinet 1994 ; 27 : 175-90
31. Pichard L, Gilllet G, Fabre I, Dalet-Beluche I, Bonfils C, Thenot JP, Maurel P. Identification of the rabbit and human cytochrome P450 IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos 1990 ; 18 : 711-19
32. Preston KL, Griffiths RR, Stitzer ML, Bigelow GE, Liebson IA. Diazepam and methadone interaction in methadone maintenance. Clin Pharmacol Ther 1984 ; 36 : 534-41
33. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Brosen K. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995 ; 39 : 151-9
34. Ring BJ, Binkley SN, Roskos L, Wrighton SA. Effect of fluoxetine, norfluoxetine, sertraline and N-desmethylsertraline on human CYP3A catalyzed 1'-hydroxy-midazolam formation in vitro. J Pharmacol Exp Ther 1995 ; 275 : 1131-5
35. Shimada T, Yamazaki H, Minura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochromes P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. 1994. J Pharmacol Exp Ther 1994 ; 270 : 414-23
36. Verebely K, Volavka J, Mule S, Resnick R. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 1975 ; 18 : 180-90
37. Von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine and by azole antifungal agents. J Clin Pharmacol 1996 ; 36 : 783-91